Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Change in Receivables: 2022-2024

Historic Change in Receivables for Mirum Pharmaceuticals (MIRM) over the last 3 years, with Dec 2024 value amounting to $11.4 million.

  • Mirum Pharmaceuticals' Change in Receivables fell 61.16% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.9 million, marking a year-over-year increase of 92.84%. This contributed to the annual value of $11.4 million for FY2024, which is 74.02% down from last year.
  • Mirum Pharmaceuticals' Change in Receivables amounted to $11.4 million in FY2024, which was down 74.02% from $44.0 million recorded in FY2023.
  • Over the past 5 years, Mirum Pharmaceuticals' Change in Receivables peaked at $44.0 million during FY2023, and registered a low of $11.4 million during FY2024.
  • Its 3-year average for Change in Receivables is $25.4 million, with a median of $20.7 million in 2022.
  • Its Change in Receivables has fluctuated over the past 5 years, first surged by 112.16% in 2023, then crashed by 74.02% in 2024.
  • Mirum Pharmaceuticals' Change in Receivables (Yearly) stood at $20.7 million in 2022, then surged by 112.16% to $44.0 million in 2023, then slumped by 74.02% to $11.4 million in 2024.